Literature DB >> 31567352

Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens.

Antonio Hernandez1, Liming Luan1, Cody L Stothers2, Naeem K Patil1, Jessica B Fults1, Benjamin A Fensterheim2, Yin Guo1, Jingbin Wang1, Edward R Sherwood1,2, Julia K Bohannon1,2.   

Abstract

OBJECTIVES: To determine whether synthetic phosphorylated hexa-acyl disaccharides provide antimicrobial protection in clinically relevant models of bacterial infection.
DESIGN: Laboratory study.
SETTING: University laboratory.
SUBJECTS: BALB/c, C57BL/10J, and C57BL/10ScNJ mice.
INTERVENTIONS: Mice were treated with lactated Ringer's (vehicle) solution, monophosphoryl lipid A, or phosphorylated hexa-acyl disaccharides at 48 and 24 hours prior to intraperitoneal Pseudomonas aeruginosa or IV Staphylococcus aureus infection. Leukocyte recruitment, cytokine production, and bacterial clearance were measured 6 hours after P. aeruginosa infection. In the systemic S. aureus infection model, one group of mice was monitored for 14-day survival and another for S. aureus tissue burden at 3 days postinfection. Duration of action for 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide was determined at 3, 10, and 14 days using a model of intraperitoneal P. aeruginosa infection. Effect of 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide on in vivo leukocyte phagocytosis and respiratory burst was examined. Leukocyte recruitment, cytokine production, and bacterial clearance were measured after P. aeruginosa infection in wild-type and toll-like receptor 4 knockout mice treated with 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide or vehicle to assess receptor specificity.
MEASUREMENTS AND MAIN RESULTS: During intraperitoneal P. aeruginosa infection, phosphorylated hexa-acyl disaccharides significantly attenuated infection-induced hypothermia, augmented leukocyte recruitment and bacterial clearance, and decreased cytokine production. At 3 days post S. aureus infection, bacterial burden in lungs, spleen, and kidneys was significantly decreased in mice treated with monophosphoryl lipid A or phosphorylated hexa-acyl disaccharides, which was associated with improved survival. Leukocyte phagocytosis and respiratory burst functions were enhanced after treatment with monophosphoryl lipid A or phosphorylated hexa-acyl disaccharides. A time course study showed that monophosphoryl lipid A- and 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide-mediated protection against P. aeruginosa lasts for up to 10 days. Partial loss of augmented innate antimicrobial responses was observed in toll-like receptor 4 knockout mice treated with 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide.
CONCLUSIONS: Phosphorylated hexa-acyl disaccharides significantly augment resistance against clinically relevant Gram-negative and Gram-positive infections via enhanced leukocyte recruitment, phagocytosis, and respiratory burst functions of innate leukocytes. Improved antimicrobial protection persists for up to 10 days and is partially mediated through toll-like receptor 4.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31567352      PMCID: PMC6791756          DOI: 10.1097/CCM.0000000000003967

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  22 in total

1.  Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells.

Authors:  Jonathan L Schmid-Burgk; Moritz M Gaidt; Tobias Schmidt; Thomas S Ebert; Eva Bartok; Veit Hornung
Journal:  Eur J Immunol       Date:  2015-08-06       Impact factor: 5.532

2.  Novel Programs and Discoveries Aim to Combat Antibiotic Resistance.

Authors:  Tracy Hampton
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

3.  The Cytokine Response to Lipopolysaccharide Does Not Predict the Host Response to Infection.

Authors:  Benjamin A Fensterheim; Yin Guo; Edward R Sherwood; Julia K Bohannon
Journal:  J Immunol       Date:  2017-03-08       Impact factor: 5.422

4.  Noncanonical inflammasome activation by intracellular LPS independent of TLR4.

Authors:  Nobuhiko Kayagaki; Michael T Wong; Irma B Stowe; Sree Ranjani Ramani; Lino C Gonzalez; Sachiko Akashi-Takamura; Kensuke Miyake; Juan Zhang; Wyne P Lee; Artur Muszyński; Lennart S Forsberg; Russell W Carlson; Vishva M Dixit
Journal:  Science       Date:  2013-07-25       Impact factor: 47.728

5.  The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism.

Authors:  Benjamin A Fensterheim; Jamey D Young; Liming Luan; Ruby R Kleinbard; Cody L Stothers; Naeem K Patil; Allison G McAtee-Pereira; Yin Guo; Irina Trenary; Antonio Hernandez; Jessica B Fults; David L Williams; Edward R Sherwood; Julia K Bohannon
Journal:  J Immunol       Date:  2018-04-23       Impact factor: 5.422

Review 6.  Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care.

Authors:  Lori F Gentile; Alex G Cuenca; Philip A Efron; Darwin Ang; Azra Bihorac; Bruce A McKinley; Lyle L Moldawer; Frederick A Moore
Journal:  J Trauma Acute Care Surg       Date:  2012-06       Impact factor: 3.313

7.  Flt3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in a Murine Model of Burn Wound Sepsis.

Authors:  Naeem K Patil; Julia K Bohannon; Liming Luan; Yin Guo; Benjamin Fensterheim; Antonio Hernandez; Jingbin Wang; Edward R Sherwood
Journal:  Shock       Date:  2017-01       Impact factor: 3.454

8.  Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.

Authors:  N Qureshi; K Takayama; E Ribi
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

Review 9.  Improving vaccine delivery using novel adjuvant systems.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin       Date:  2008-02-15

10.  Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury.

Authors:  Julia K Bohannon; Liming Luan; Antonio Hernandez; Aqeela Afzal; Yin Guo; Naeem K Patil; Benjamin Fensterheim; Edward R Sherwood
Journal:  J Leukoc Biol       Date:  2015-11-04       Impact factor: 4.962

View more
  6 in total

Review 1.  Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection.

Authors:  Antonio Hernandez; Naeem K Patil; Cody L Stothers; Liming Luan; Margaret A McBride; Allison M Owen; Katherine R Burelbach; David L Williams; Edward R Sherwood; Julia K Bohannon
Journal:  Pharmacol Res       Date:  2019-11-02       Impact factor: 7.658

2.  β-Glucan Induces Distinct and Protective Innate Immune Memory in Differentiated Macrophages.

Authors:  Cody L Stothers; Katherine R Burelbach; Allison M Owen; Naeem K Patil; Margaret A McBride; Julia K Bohannon; Liming Luan; Antonio Hernandez; Tazeen K Patil; David L Williams; Edward R Sherwood
Journal:  J Immunol       Date:  2021-11-05       Impact factor: 5.426

3.  Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.

Authors:  Robert E Haupt; Erin M Harberts; Robert J Kitz; Shirin Strohmeier; Florian Krammer; Robert K Ernst; Matthew B Frieman
Journal:  Vaccine       Date:  2021-08-03       Impact factor: 4.169

Review 4.  The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma.

Authors:  Margaret A McBride; Allison M Owen; Cody L Stothers; Antonio Hernandez; Liming Luan; Katherine R Burelbach; Tazeen K Patil; Julia K Bohannon; Edward R Sherwood; Naeem K Patil
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

Review 5.  Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression.

Authors:  Margaret A McBride; Tazeen K Patil; Julia K Bohannon; Antonio Hernandez; Edward R Sherwood; Naeem K Patil
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

Review 6.  TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.

Authors:  Allison M Owen; Jessica B Fults; Naeem K Patil; Antonio Hernandez; Julia K Bohannon
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.